

1 Michael J. McCue (NV Bar No. 6055)  
mmccue@lrlaw.com  
2 Jonathan W. Fountain (NV Bar No. 10351)  
jfountain@lrlaw.com  
3 LEWIS AND ROCA LLP  
4 3993 Howard Hughes Parkway, Suite 600  
Las Vegas, Nevada 89169  
5 (702) 949-8200 (phone)  
(702) 949-8398 (facsimile)  
6

7 Of Counsel:

8 Adam K. Mortara (*pro hac vice* application to be filed)  
adam.mortara@bartlit-beck.com  
9 J. Scott McBride (*pro hac vice* application to be filed)  
scott.mcbride@bartlit-beck.com  
10 Asha L.I. Spencer (*pro hac vice* application to be filed)  
asha.spencer@bartlit-beck.com  
11 BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP  
12 54 West Hubbard Street  
Chicago, Illinois 60654  
13 (312) 494-4400 (phone)  
(312) 494-4440 (facsimile)  
14

15 Attorneys for Plaintiffs Merck & Cie, Bayer Pharma AG  
and Bayer HealthCare Pharmaceuticals Inc.

16 **UNITED STATES DISTRICT COURT**

17 **DISTRICT OF NEVADA**

19 MERCK & CIE, BAYER PHARMA AG, and  
BAYER HEALTHCARE  
20 PHARMACEUTICALS INC.,

21 Plaintiffs,

22 vs.

23 WATSON LABORATORIES, INC., and  
24 ACTAVIS, INC.,

25 Defendants.

**COMPLAINT FOR  
PATENT INFRINGEMENT**

**(JURY DEMAND)**

26 Plaintiffs Merck & Cie, Bayer Pharma AG, and Bayer HealthCare Pharmaceuticals Inc.,  
27 for their Complaint for patent infringement herein against Defendants Watson Laboratories, Inc.  
28 and Actavis, Inc. allege as follows:

1 **PARTIES**

2 1. Plaintiff Merck & Cie (“Merck”) is a Swiss corporation having a principal place of  
3 business at Weisshausmatte 6460 Altdorf, Switzerland.

4 2. Plaintiff Bayer Pharma AG (“Bayer Pharma”), formerly known as Schering AG, is  
5 a corporation organized and existing under the laws of the Federal Republic of Germany, having a  
6 principal place of business at Müllerstrasse 178, 13353 Berlin, Germany.

7 3. Plaintiff Bayer HealthCare Pharmaceuticals Inc. (“Bayer HealthCare”), formerly  
8 known as Berlex, Inc., is a corporation organized and existing under the laws of the State of  
9 Delaware, having a principal place of business at 340 Changebridge Road, P.O. Box 1000,  
10 Montville, New Jersey 07045-1000.

11 4. On information and belief, Defendant Actavis, Inc. (“Actavis”) is a corporation  
12 organized and existing under the laws of the State of Nevada, having a principal place of business  
13 at 311 Bonnie Circle, Corona, California 92880. Defendant Actavis develops, manufactures, and  
14 markets generic pharmaceutical products through its operating subsidiary Defendant Watson  
15 Laboratories, Inc.

16 5. On information and belief, Defendant Watson Laboratories, Inc. (“Watson Labs.”)  
17 is a corporation organized and existing under the laws of the State of Nevada, having a principal  
18 place of business at 311 Bonnie Circle, Corona, California 92880.

19 6. On information and belief, Defendant Watson Labs. is a wholly-owned subsidiary  
20 of Defendant Actavis, and the two have common officers and directors.

21 7. On information and belief, Defendant Actavis directed, authorized, participated in,  
22 assisted and cooperated with Defendant Watson Labs. in all of the acts complained of herein.  
23 Hereinafter, Defendants Actavis and Watson Labs. are collectively referred to as “Watson.”

24 **JURISDICTION AND VENUE**

25 8. This action arises under the patent laws of the United States of America. This  
26 Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a).

27 9. This Court has personal jurisdiction over Defendants Actavis and Watson Labs. by  
28 virtue of, inter alia, the fact that they regularly transact and solicit business in Nevada, have

1 consented to jurisdiction in Nevada in cases arising out of the filing of their ANDAs, and have  
2 purposefully availed themselves of this forum such that they should reasonably anticipate being  
3 haled into Court here.

4 10. On information and belief, Actavis has consolidated its activities and financial  
5 results in its most recent SEC filings and Annual Report with, among other entities, Watson Labs.

6 11. On information and belief, Actavis and Watson Labs. earn revenue from the  
7 distribution in Nevada of generic pharmaceutical products that are manufactured by Watson Labs.  
8 On information and belief, various products for which Watson Labs. is the named applicant on  
9 approved ANDAs are available at retail pharmacies in Nevada and elsewhere through a link  
10 provided on Actavis' website.

11 12. Venue is proper in this judicial district under 28 U.S.C. §§ 1391(b) and (c), and  
12 § 1400(b).

### 13 **BACKGROUND**

14 13. Bayer HealthCare is the holder of approved New Drug Application (“NDA”) No.  
15 022532, for Beyaz®, which contains as active ingredients drospirenone, 17 $\alpha$ -ethinyl estradiol, and  
16 levomefolate calcium. Beyaz® tablets have been approved by the United States Food and Drug  
17 Administration (“FDA”) to prevent pregnancy in women who elect to use an oral contraceptive,  
18 and to provide a daily dose of folate supplementation. Beyaz® tablets are sold in the United  
19 States by Bayer HealthCare as a 28-day oral contraceptive regimen that contains 24 tablets  
20 comprising 3 mg of micronized drospirenone, 0.02 mg of micronized 17 $\alpha$ -ethinyl estradiol, and  
21 0.451 mg levomefolate calcium plus 4 tablets comprising 0.451 mg levomefolate calcium.

22 14. On information and belief, Watson submitted to the FDA Abbreviated New Drug  
23 Application (“ANDA”) No. 203593 under the provisions of 21 U.S.C. § 355(j), seeking approval  
24 to engage in the commercial manufacture, use, offer for sale, sale and/or importation of a generic  
25 version of Bayer HealthCare's Beyaz® tablets.

26 15. On information and belief, the composition of the product that is the subject of  
27 Watson's ANDA is for oral contraception in a human female and contains tablets comprising 3 mg  
28 of drospirenone, 0.02 mg of 17 $\alpha$ -ethinyl estradiol, and 0.451 mg levomefolate calcium, and tablets

1 comprising 0.451 mg levomefolate calcium.

2 16. On information and belief, Watson's ANDA seeks approval of a 28-day oral  
3 contraceptive regimen that contains 24 tablets comprising 3 mg of drospirenone, 0.02 mg of 17 $\alpha$ -  
4 ethinyl estradiol, and 0.451 mg levomefolate calcium, and 4 tablets comprising 0.451 mg  
5 levomefolate calcium (hereinafter "Watson's ANDA product").

6 17. On information and belief, on or about June 19, 2013, Watson sent a Notice Letter  
7 to Plaintiffs Merck, Bayer Pharma, and Bayer HealthCare, purporting to comply with the  
8 provisions of 21 U.S.C. § 355(j)(2)(B) and the FDA regulations relating thereto.

9 18. The patent-in-suit is U.S. Patent No. 6,441,168 (the "'168 Patent") (attached hereto  
10 as Exhibit 1). Inventors Rudolf Müller, Rudolf Moser, and Thomas Egger filed their application  
11 for this patent on April 17, 2000. The '168 Patent was issued August 27, 2002. Merck & Cie is  
12 the current owner of the '168 Patent.

13 19. Bayer Pharma is the exclusive licensee of the '168 Patent for the sectors of  
14 gynecology and andrology, for the indications fertility control, hormone therapy, and hormone  
15 replacement therapy (with the exception of oncological indications). Bayer Pharma is also the  
16 exclusive licensee of the '168 Patent for the indications listed above as a primary indication in  
17 combination with secondary indications within the same product.

18 20. Bayer HealthCare markets Beyaz® in the United States under Bayer Pharma's  
19 exclusive license.

20  
21 **COUNT ONE: CLAIM FOR PATENT INFRINGEMENT OF**  
**UNITED STATES PATENT NO. 6,441,168**

22 21. Plaintiffs incorporate all preceding paragraphs of this Complaint as if fully set forth  
23 herein.

24 22. On information and belief, Watson's ANDA product infringes one or more claims  
25 of the '168 Patent.

26 23. The '168 Patent covers Bayer HealthCare's Beyaz® tablets and has been listed for  
27 the product in the FDA *Approved Drug Products with Therapeutic Equivalence Evaluations* ("the  
28 Orange Book").



1 attorneys and employees, and those acting in privity or concert with it, from engaging in the  
2 commercial manufacture, use, offer to sell, or sale within the United States, or importation into the  
3 United States, of Watson's ANDA product;

4 C. An order that the effective date of any approval of Watson's ANDA relating to  
5 Watson's ANDA product containing drospirenone, ethinyl estradiol, and levomefolate calcium, be  
6 a date which is not earlier than the expiration date of the '168 Patent or any later date of  
7 exclusivity to which Plaintiffs become entitled;

8 D. Damages from Watson for any commercial activity constituting infringement of the  
9 '168 Patent; and

10 E. Such other and further relief as the Court may deem just and proper.

11 **JURY DEMAND**

12 Plaintiffs hereby demand a jury trial on all issues so triable.

13 DATED: this 24th day of July, 2013.

14 LEWIS AND ROCA LLP

15 By: /s/ Jonathan W. Fountain

16 Michael J. McCue (NV Bar No. 6055)  
17 Jonathan W. Fountain (NV Bar No. 10351)  
18 3993 Howard Hughes Parkway, Suite 600  
19 Las Vegas, Nevada 89169

20 Of Counsel:

21 BARTLIT BECK HERMAN PALENCHAR & SCOTT LLP

22 Adam K. Mortara (*pro hac vice* application to be filed)  
23 J. Scott McBride (*pro hac vice* application to be filed)  
24 Asha L.I. Spencer (*pro hac vice* application to be filed)  
25 54 West Hubbard Street  
26 Chicago, Illinois 60654

27 Attorneys for Plaintiffs Merck & Cie, Bayer Pharma AG,  
28 and Bayer HealthCare Pharmaceuticals Inc.